Screen Shot 2019-07-24 at 11.23.50 am.png

BioShares | Imugene To Expand Portfolio With License of Oncolytic Virotherapy

July 22, 2019


Screen Shot 2019-08-01 at 10.25.55 am.png

BioWorld | Aussie immuno-oncology firm Imugene bolsters pipeline with oncolytic virus acquisition

July 17, 2019


Edison Research Note | In-Licensing deal for CF33 oncolytic virus

July 15, 2019


Screen Shot 2019-07-14 at 4.03.50 pm.png

Australian Research Independent Investment Research | Imugene Limited (ASX: IMU) Initiating Coverage

July 15, 2019


Screen Shot 2019-07-15 at 2.18.23 pm.png

Edison Research Note | HER-Vaxx Phase II underway

April 15, 2019


Screen Shot 2018-10-29 at 12.30.17 pm.png

BioShares | Imugene prepares for Phase IIa Study

September 14, 2018


Screen Shot 2019-07-15 at 2.20.07 pm.png

Edison Research Note | Checkpoint inhibitor vaccine programme accelerated

August 16, 2018


Screen Shot 2018-10-29 at 12.51.56 pm.png

BioWorld | Aussie biotech Imugene leads pack in HER2-targeting B-cell immunotherapies

January 22, 2018


Screen Shot 2018-10-29 at 12.56.22 pm.png

BioShares | Imugene Set To Commence Phase Ib/II Gastric Cancer Trial

June 3, 2016


Screen Shot 2018-10-29 at 12.59.34 pm.png

Red Chip Research Report | Anti-tumour vaccine trial to start mid-2016

April 18, 2016


Screen Shot 2018-10-29 at 1.08.47 pm.png

Edison Research Note | Anti-tumour vaccine trial to start mid-2016

February 19, 2016


Screen Shot 2018-10-29 at 1.12.33 pm.png

BioShares | Imugene Adopts a Portfolio Model to Become a B Cell Vaccines Play

January 22, 2016